Shots:

• Merck KGaA divests its allergy business- Allergopharm to Dermapharm to focus on developing innovative therapies targeting the unmet medical needs of patients with difficult-to-treat diseases. The transaction is anticipated to be close in Q2’20
• The divestiture will not include Allergopharma's adrenaline autoinjector development project for treating anaphylactic reactions and will retain by Merck. The transaction incorporates Allergopharm’s therapeutic and diagnostic product portfolio in the EU & Asia with its production site in Germany
• Allergopharma develops allergen-specific immunotherapy of type 1 allergies like hay fever or allergic asthma and has generated the annual sales of $95M with the availability of its product in 18 countries globally

Click here ­to­ read full press release/ article 

 Ref: Merck KGaA | Image: Merck KGaA